Research Reports

Prepared Highlights

Q2 2026 consolidated net revenues: $5.6 billion; adjusted EBITDA: $1.304 billion, margin 23.2%, growth 16.3% YoY (CEO, CFO)
YTD fundamental outperformance: ~$97 million across both segments (CEO)
Adjusted diluted EPS: $6.12, up 52% YoY (CEO)
USPI segment Q2: adjusted EBITDA $542 million, +8.8% YoY, margin 39%; same-facility system-wide revenues +5%, net revenue per case +6.3%, case volumes −1.2% (CFO)
USPI high-acuity growth: total joint replacements same-store volumes +10% YoY in ASCs (CEO)
Hospital segment Q2: adjusted EBITDA $762 million, +22% YoY, margin 18%; same-hospital inpatient adjusted admissions +2.6%, revenue per adjusted admission +3.3% (CFO)
Exchange revenue headwind: −17% YoY in Q2, representing 5.5% of consolidated net revenues; highest impact in FL, AZ, MI, SC, TX (CEO, CFO)
Supplemental Medicaid: $92 million favorable out-of-period revenues in Q2 (prior-year Q2: $70 million) (CFO)
Cash and capital deployment: Q2 adjusted free cash flow $444 million; YTD $1.4 billion; $2.1 billion cash on hand; 6/30/26 leverage ratio 2.33x EBITDA (CFO)
Share repurchases: 5.7 million shares ($1.04 billion) in Q2; YTD 7 million shares ($1.36 billion); Board authorized $2 billion increase in repurchase program (CEO, CFO)
Full-year guidance raise: consolidated net revenues $21.9–$22.5 billion (+$300M at midpoint); adjusted EBITDA $4.83–$5.03 billion (+$295M at midpoint); adjusted free cash flow after NCI $1.825–$2.055 billion (+$225M at midpoint) (CEO, CFO)

Official Guidance (FY 2026)

Consolidated net operating revenues: $21.9 billion – $22.5 billion (CFO)
Consolidated adjusted EBITDA: $4.83 billion – $5.03 billion (CEO, CFO)
USPI adjusted EBITDA: $2.16 billion – $2.22 billion (CFO)
Hospital segment adjusted EBITDA: $2.67 billion – $2.81 billion (+$285M at midpoint) (CFO)
Adjusted free cash flow after NCI: $1.825 billion – $2.055 billion (includes ~$150M tax payments from Conifer transaction) (CFO)
Q3 2026 adjusted EBITDA: 23%–24% of full-year consolidated; USPI EBITDA 24%–25% of full-year USPI (CFO)
Supplemental Medicaid contribution: $140 million (of which ~$20 million in H2) (CFO)

Mgmt Quotes

“We continue to deliver results exceeding our goals based on the fundamental performance of our business.” – (CEO)
“USPI is the premier ambulatory surgical asset in the space and the leading provider of low-cost, high-quality care.” – (CEO)
“Our consistent results are driven by a transformed portfolio… and an ability to effectively manage through the current dynamic environment.” – (CEO)
“We feel our shares are still very well discounted based on the free cash flow yield.” – (CFO)
“We are well positioned to create value for shareholders through the effective deployment of free cash flow.” – (CFO)

Prepared Metrics

Metric	Value	Source/Context
Q2 Net Revenues	$5.6 billion	CEO, CFO
Q2 Adj. EBITDA	$1.304 billion	CEO, CFO
Q2 Adj. EBITDA Margin	23.2%	CEO
Q2 Adj. EPS	$6.12 (+52% YoY)	CEO
USPI Q2 Adj. EBITDA	$542 million (+8.8% YoY)	CFO
USPI Q2 Adj. EBITDA Margin	39%	CFO
USPI Same-facility Revenue Growth	+5% YoY	CFO
Hospital Q2 Adj. EBITDA	$762 million (+22% YoY)	CFO
Hospital Q2 Adj. EBITDA Margin	18%	CEO
Same-hospital Inpatient Adj. Admissions Growth	+2.6% YoY	CFO
Exchange Revenue Decline (Q2)	−17% vs Q2 '25; 5.5% of net revs	CFO
Q2 Adj. Free Cash Flow	$444 million	CFO
YTD Adj. Free Cash Flow (H1 2026)	$1.4 billion	CFO
6/30/26 Cash on Hand	$2.1 billion	CFO
Leverage Ratio (6/30/26)	2.33x EBITDA	CFO
YTD Share Repurchases (H1 '26)	7 million shares / $1.

Q&A Batch (1-1 of 1)

Q1 — Justin Lake

Topic: 营收增长驱动因素（商业雇主/Medicaid细分）及下半年盈利指引
Key points:
- 商业雇主组（非Exchange）收入同比低个位数增长（“low single digits” quarter-over-quarter），但整体Managed Care类别因Exchange影响收入占比下降2.7个百分点。
- Medicaid收入同比增加约1.25亿美元，其中9,000万美元为“out‑of‑period”项目；去年同期Q2有7,000万美元，因此净增量约2,000–2,500万美元来自out‑of‑period。其余增量来自新增项目（如Florida项目）以及服务量增长、项目调整和时点因素。
- 医院分部盈利指引：假设下半年收益约为上半年已实现收益的一半左右（“the second half benefit is just over about half of what you recognized in first...”）。
Mgmt stance: 中性偏积极。管理层强调增长源于对高难度病种的持续投资（创伤、NICU等），并认为州定向支付计划（SPP）收入应视为核心收入的一部分，但对未来Medicaid增速不予量化，仅描述结构性原因。